Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 8;13(17):5314.
doi: 10.3390/jcm13175314.

Androgen Deprivation Therapy and the Risk of Newly Developed Dry Eye Syndrome in Patients with Prostate Cancer: A Nationwide Nested Case-Control Study in the Republic of Korea

Jinhyung Jeon  1 , Jee Soo Ha  2 , Hye Sun Lee  3 , Soyoung Jeon  3 , Ho Sik Hwang  4 , Daeho Kim  1 , June Seok Kim  1 , Byeong Seon Kim  5 , Min Kim  6 , Kang Su Cho  1   7
Affiliations

Androgen Deprivation Therapy and the Risk of Newly Developed Dry Eye Syndrome in Patients with Prostate Cancer: A Nationwide Nested Case-Control Study in the Republic of Korea

Jinhyung Jeon et al. J Clin Med. .

Abstract

Background: We aimed to evaluate the association between androgen deprivation therapy (ADT) and newly developed dry eye syndrome (DES) in patients with prostate cancer. Methods: A nested case-control study was conducted. From the nationwide claims database of the Republic of Korea, 125,005 patients were included in the final analysis. Cases were defined as those newly diagnosed with DES during follow-up, and 12,654 patients were identified. The cases were matched with controls in a ratio of 1:4. Odds ratios (ORs) for newly developed DES associated with ADT were estimated using conditional logistic regression. Results: After matching, 7499 cases and 29,996 controls were selected. ADT was associated with a reduced risk of newly developed DES in patients with prostate cancer compared to no ADT (OR = 0.875; 95% confidence interval, 0.825-0.927; p < 0.0001). An accumulated dose of ADT < 1 year was associated with a reduced risk of incidental DES (OR = 0.811; 95% CI, 0.751-0.875; p < 0.0001), and a duration of 1-2 years was also associated with a reduced risk (OR = 0.890; 95% CI, 0.802-0.986; p = 0.026). No association was observed with an ADT duration of ≥2 years. Conclusions: The use of ADT, especially for shorter durations (<2 years), was associated with a reduced risk of newly developed DES in S. Korean patients with prostate cancer.

Keywords: androgen deprivation therapy; androgens; case–control studies; dry eye syndromes; prostate neoplasms.

PubMed Disclaimer

Conflict of interest statement

The authors report there are no competing interests to declare.

Figures

Figure 1
Figure 1
Flow diagram of the study cohort. RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjogren’s syndrome.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Handelsman D.J. Androgen physiology, pharmacology, use and misuse. In: Feingold K.R., Anawalt B., Blackman M.R., Boyce A., Chrousos G., Corpas E., de Herder W.W., Dhatariya K., Dungan K., Hofland J., et al., editors. Endotext. MDText.com, Inc.; South Dartmouth, MA, USA: 2000. - PubMed
    1. Heinlein C.A., Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 2004;25:276–308. doi: 10.1210/er.2002-0032. - DOI - PubMed
    1. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 1972;22:232–240. doi: 10.3322/canjclin.22.4.232. - DOI - PubMed
    1. Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. J. Am. Med. Assoc. 2005;294:238–244. doi: 10.1001/jama.294.2.238. - DOI - PubMed
    1. McLeod D.G. Hormonal therapy: Historical perspective to future directions. Urology. 2003;61:3–7. doi: 10.1016/S0090-4295(02)02393-2. - DOI - PubMed

LinkOut - more resources